Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKinsey
Merck
Dow
McKesson

Last Updated: December 6, 2019

DrugPatentWatch Database Preview

Litigation Details for SUMITOMO DAINIPPON PHARMA CO., LTD. v. EMCURE PHARMACEUTICALS LIMITED (D.N.J. 2015)

See Plans and Pricing

« Back to Dashboard

SUMITOMO DAINIPPON PHARMA CO., LTD. v. EMCURE PHARMACEUTICALS LIMITED (D.N.J. 2015)

Docket   Start Trial Date Filed 2015-01-14
Court District Court, D. New Jersey Date Terminated 2017-02-28
Cause 35:145 Patent Infringement Assigned To Stanley R. Chesler
Jury Demand None Referred To Cathy L. Waldor
Parties EMCURE PHARMACEUTICALS LIMITED; EMCURE PHARMACEUTICALS USA, INC.; INVAGEN PHARMACEUTICALS, INC.; SUMITOMO DAINIPPON PHARMA CO., LTD.; SUNOVION PHARMACEUTICALS INC.; TEVA PHARMACEUTICAL INDUSTRIES, LTD.; TEVA PHARMACEUTICALS USA, INC.
Patents 5,532,372
Attorneys AMAR A. MEHTA; CHARLES MICHAEL LIZZA; DAVID C. KISTLER; GARY J. RUCKELSHAUS; JASON TODD CHRISTIANSEN; JAY P. LESSLER; MAYRA VELEZ TARANTINO; MICHAEL E. PATUNAS; SALVATORE R. GUERRIERO; SARAH ANN SULLIVAN; STEPHEN M. ORLOFSKY; WILLIAM C. BATON
Firms Adamas Pharmaceuticals, Inc.; Blank Rome LLP, the Chrysler Building; Heritage Pharmaceuticals Inc.; Ice Miller LLP; Patunas Law LLC; Patunas Tarantino LLC; Paul Hastings LLP; Salvatore R. Guerriero; Saul Ewing Arnstein & Lehr LLP
Link to Docket External link to docket
Small Molecule Drugs cited in SUMITOMO DAINIPPON PHARMA CO., LTD. v. EMCURE PHARMACEUTICALS LIMITED
The small molecule drug covered by the patent cited in this case is   Start Trial .

Details for SUMITOMO DAINIPPON PHARMA CO., LTD. v. EMCURE PHARMACEUTICALS LIMITED (D.N.J. 2015)

Date Filed Document No. Description Snippet Link To Document
0000-00-00 1 United States Patent No. 5,532,372 (“the ’372 patent”). This action arises under the Patent Laws of the…Number: 5,532,372 Saji et al. … 5,532,372 1 … 5,532,372 3 … 5,532,372 5 External link to document
2016-08-25 101 · · ·Patent Number 5,532,372.) ·9 …claim construction process of the Local Patent Rules. The Local Patent Rules provide for a progressive process…should not be rewarded for flouting the local patent rules. B. The Extreme Sanction … the analysis in the context of purported Local Patent Rule violations. See Shire LLC v. Amneal Pharms…Evidence • The specification of the ’372 patent, including, without limitation: 3:3-4:43, 4:44- External link to document
0000-00-00 106 construction of claim 14 in U.S. Patent No. 5,532,372 (“the ’372 patent”). …intrinsic to the patent (the patent claims and specifications, along with the patent’s prosecution history…Industries, Ltd. In this patent infringement suit involving a pharmaceutical patent, the parties seek construction… It is a bedrock principle of patent law that the claims of a patent define the invention to…construction A court’s determination “of patent infringement requires a two-step process: first External link to document
0000-00-00 138 prior to the expiration of U.S. Patent No. 5,532,372 (“the ’372 patent”); WHEREAS, Defendants Teva Pharmaceuticals…’372 patent.’ Such challenges to the patentability, validity, or enforceability of the 372 patent include…expiration of the 372 patent were each an act of infringement of Claim 14 of the ’372 patent under 35 U.S.C…indirectly, challenge the patentability, validity, or enforceability of the °372 patent in this or any other… (a) challenge the patentability, validity, or enforceability of the ’372 patent; and/or (b) assist, External link to document
0000-00-00 141 prior to the expiration of U.S. Patent No. 5,532,372 (“the °372 patent”); WHEREAS, Plaintiffs Sumitomo…372 patent.’ Such challenges to the patentability, validity, or enforceability of the ’372 patent include…expiration of the ’372 patent was an act of infringement of Claim 14 of the ’372 patent under 35 U.S.C. §…indirectly, challenge the patentability, validity, or enforceability of the °372 patent in this or any other…: (a) challenge the patentability, validity, or enforceability of the °372 patent; and/or (b) assist, External link to document
2016-08-15 98 infringement of Claim 14 of U.S. Patent No. 5,532,372 (“the ’372 patent”). Defendants Emcure and Teva…infringement of Claim 14 of U.S. Patent No. 5,532,372 (“the ’372 patent”). Defendants deny all salient …A. U.S. Patent No. 5,532,372 (Claim 14) …Disputed Term U.S. Patent No. 5,532,372 (Claim 14) Claim Term or Phrase … 1219 U.S. Patent No. 5,532,372 (Claim 14) Claim Term or Phrase External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Mallinckrodt
Boehringer Ingelheim
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.